Results for status epilepticus translation from English to Maltese

status epilepticus
dispnea

status
l-istatus

mrl status
stat tal-mrl

acetylation status
stat ta’ acetylation

1 (1) grand mal convulsions, status epilepticus)
1 (1)

seizures (including convulsions, grand mal convulsions, status epilepticus)
aċċessjonijiet (li jinkludu konvulżjonijiet, konvulżjonijiet grand mal,status epilepticus)

administration of a loading dose has not been studied in patients with status epilepticus
it-teħid ta’ doża kbira tal-bidu ma ġietx studjata b’pazjenti b’stat epilettiku.

administration of a loading dose has not been studied in patients with status epilepticus.
it-teħid ta’ doża kbira tal-bidu ma ġietx studjata f’pazjenti b’ stat epilettiku.

one subject in the paediatric group had a fatal neurological event of status epilepticus.
suġġett mill- grupp pedjatriku kellu effett newroloġiku fatali ta 'status epilepticus

administration of a loading dose has not been studied in acute conditions such as status epilepticus.
it-teħid ta’ doża kbira tal-bidu ma ġietx studjata f’kondizzjonijiet akuti bħal-stat epilettiku.

the effectiveness of pexion to treat dogs with status epilepticus and cluster seizures has not been studied.
l-effikaċja ta' pexion għall-kura ta' klieb b'epileptikus tal-istatus u b'aċċessjonijiet f'daqqa ma ġietx studjata.

therefore, imepitoin should not be used as primary treatment in dogs with cluster seizures and status epilepticus.
għalhekk, imepitoin m’għandux jintuża bħala l-kura primarja fi klieb b’puplesiji li jiġu waħda wara l-oħra f’perjodu qasir ta’ żmien u status epilepticus.

the efficacy of the veterinary medicinal product in dogs with status epilepticus and cluster seizures has not been investigated.
l-effikaċja tal-prodott veterinarju fil-klieb bi status epilepticus u puplesiji li jiġu waħda wara l-oħra f’perjodu qasir ta’ żmien ma ġietx investigata.

amnesia coma grand mal seizure myasthenic syndrome neuroleptic malignant syndrome status epilepticus dyspnoea pneumonia aspiration respiratory disorder
atassja

convulsions, including status epilepticus and grand mal convulsions, may occur during pregabalin use or shortly after discontinuing pregabalin.
aċċessjonijiet li jinkludu status epilepticus u dawk tat-tip grand mal jistgħu jinqalgħu waqt l-użu ta’ pregabalin jew ftit wara li twaqqfet il-kura bi pregabalin.

status epilepticus cases have been observed during clinical development studies, under rufinamide whereas no such cases have been observed under placebo.
każijiet ta’ status epilepticus kienu osservati waqt l-istudji ta’ żvilupp kliniku, b’rufinamide, filwaqt li l-ebda każ ma ġie osservat bi plaċebo.

central nervous system side effects at high doses of 4-aminopyridine include confusion, seizures, status epilepticus, involuntary and choreoathetoid movements.
l-effetti sekondarji fis-sistema nervuża ċentrali f’dożi għoljin ta’ 4-aminopyridine jinkludu konfużjoni, puplesiji, stat epilettiku, movimenti involontarji u koreoatetojdi.

there are reports in the literature that severe convulsive seizures including status epilepticus may lead to rhabdomyolysis, multiorgan dysfunction and disseminated intravascular coagulation, sometimes with fatal outcome.
fil- letteratura jeżistu rapporti li jgħidu li attakki qawwija konvulsivi inkluż l- istatus epilepticus jistgħu iwasslu għal rabdomilosi, disfunzjoni multiorganika u tixrid ta ’ koagulazzjoni tad- demm fil- vini, xi drabi b’ konsegwenzi fatali.

in addition, retigabine was effective in preventing status epilepticus seizures in rodents with cobalt-induced epileptogenic lesions, and inhibiting tonic extensor seizures in genetically susceptible mice.
barra dan, retigabine kien effettiv fil-prevenzjoni ta’ aċċessjonijiet status epilepticus fl-annimali gerriema b’leżjonijiet epileptoġeniċi indotti bil-cobalt, u impedixxa aċċessjonijiet tonic extensor fi ġrieden ġenetikament suxxettibbli.

if patients develop new seizure types and/or experience an increased frequency of status epilepticus that is different from the patient’s baseline condition, then the benefit risk ratio of the therapy should be reassessed.
jekk pazjenti jiżviluppaw tipi ġodda ta’ aċċessjonijiet u/jew frekwenza akbar ta’ status epilepticus li hi differenti mill-linja bażi tal-kundizzjoni ta’ riferiment tal-pazjent, allura l-proporzjon ta’ riskju ta’ benefiċċju tat-terapija għandha tiġi assessjata mill-ġdid.